46 results on '"Shandil, Radha"'
Search Results
2. Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteria
3. Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.
4. Picolinic acid is a broad-spectrum inhibitor of enveloped virus entry that restricts SARS-CoV-2 and influenza A virus in vivo
5. Apramycin kills replicating and non-replicating Mycobacterium tuberculosis.
6. Discovery of Species-Specific Proteotypic Peptides To Establish a Spectral Library Platform for Identification of Nontuberculosis Mycobacteria from Mass Spectrometry-Based Proteomics
7. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis
8. Development and validation of LC/MS/MS method for Triciribine and its monophosphate metabolite in plasma and RBC: Application to mice pharmacokinetic studies
9. Genomic Mutations in SARS-CoV-2 Genome following Infection in Syrian Golden Hamster and Associated Lung Pathologies
10. Novel Baicalein-Derived Inhibitors of Plasmodium falciparum
11. A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.
12. Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria
13. Design and synthesis of Diphenyl-1H-imidazole analogs towards SARS CoV-2 3CLpro inhibition for the treatment of COVID-19
14. A Live Attenuated COVID-19 Candidate Vaccine for Children: Protection against SARS-CoV-2 Challenge in Hamsters
15. In-Vitro Screening of Repurposed Drug Library against Severe Acute Respiratory Syndrome Coronavirus-2
16. Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases
17. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
18. Two Decades of TB Drug Discovery Efforts—What Have We Learned?
19. Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis
20. Study of the interaction between bacteriophage T4 asiA and Escherichia coli sigma (super)70, using the yeast two-hybrid system: neutralization of asiA toxicity to E. coli cells by coexpression of a truncated sigma (super)70 fragment
21. Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity
22. Whole cell screen based identification of spiropiperidines with potent antitubercular properties
23. Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis
24. Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense
25. Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway
26. In Silico -Based High-Throughput Screen for Discovery of Novel Combinations for Tuberculosis Treatment
27. 1,4-Azaindole, a Potential Drug Candidate for Treatment of Tuberculosis
28. Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship andIn VivoEfficacy in a Mouse Model of Tuberculosis
29. Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents
30. 4-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity
31. Pharmacokinetic and Pharmacodynamic Evaluation of AZD5847 in a Mouse Model of Tuberculosis
32. Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In Vivo Efficacy in a Mouse Model of Tuberculosis
33. Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo
34. In Vitro and In Vivo Efficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis
35. Aerosol Infection Model of Tuberculosis in Wistar Rats
36. Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy
37. Isoniazid Pharmacokinetics-Pharmacodynamics in an Aerosol Infection Model of Tuberculosis
38. High-Throughput Screen for Inhibitors of Transglycosylase and/or Transpeptidase Activities of Escherichia coli Penicillin Binding Protein 1b
39. Azaindoles: Noncovalent DprE1Inhibitors from Scaffold Morphing Efforts, Kill Mycobacteriumtuberculosisand Are Efficacious in Vivo.
40. Study of the Interaction between Bacteriophage T4 asiA andEscherichia coliς70, Using the Yeast Two-Hybrid System: Neutralization of asiA Toxicity toE. coliCells by Coexpression of a Truncated ς70Fragment
41. CYTOPATHOGENICITY OF ENTAMOEBA HISTOLYTICA TO HUMAN INTESTINAL EPITHELIAL CELLS: INHIBITION BY MONOCLONAL ANTIBODIES AND SERA FROM AMOEBIC PATIENTS
42. Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In VivoEfficacy in a Mouse Model of Tuberculosis
43. In Vitroand In VivoEfficacy of β-Lactams against Replicating and Slowly Growing/Nonreplicating Mycobacterium tuberculosis
44. High-Throughput Screen for Inhibitors of Transglycosylase and/or Transpeptidase Activities of Escherichia coliPenicillin Binding Protein 1b
45. Optimization of Pyrrolamides as Mycobacterial GyrB ATPase Inhibitors: Structure-Activity Relationship and In VivoEfficacy in a Mouse Model of Tuberculosis
46. A Novel Inhibitor against the Biofilms of Non-Tuberculous Mycobacteria.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.